Clinical Trials
77 trialsNCT04105374 2026-05-07
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
NRG Oncology
Phase 2/3 Withdrawn
NCT07553520 2026-04-28
Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients
UNC Lineberger Comprehensive Cancer Center
Phase NA Withdrawn
NCT04482933 2026-02-10
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
Phase 2 Withdrawn
NCT05341947 2025-10-22
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Withdrawn
NCT04118036 2025-08-11
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06501911 2025-07-22
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
University of Nebraska
Phase 1 Withdrawn
NCT04838782 2025-07-08
Role of Repeat Resection in Recurrent Glioblastoma
University of Alberta
Phase NA Withdrawn
NCT05927610 2025-05-21
Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Withdrawn
NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
NCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05879120 2024-11-20
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05773664 2024-09-19
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT01622764 2024-05-06
89Zr-RO5323441 PET Imaging in Glioblastoma
University Medical Center Groningen
Phase 2 Withdrawn
NCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT05666349 2024-03-26
RiNG
University College, London
Phase 1 Withdrawn
NCT04629209 2023-11-24
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT02432417 2023-11-18
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Maastricht Radiation Oncology
Phase 2 Withdrawn
NCT05054400 2023-09-01
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT04741984 2023-05-15
DEMAND
Duke University
Phase 1 Withdrawn
NCT05410301 2023-04-21
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
University of Iowa
Phase NA Withdrawn
NCT03956706 2023-03-15
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
Northwell Health
Phase NA Withdrawn
NCT05218408 2023-02-16
CYNK001GBM02
Celularity Incorporated
Phase 1/2 Withdrawn
NCT05017610 2022-12-02
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Emory University
Phase EARLY_PHASE1 Withdrawn
NCT03649464 2022-10-07
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
Phase 1/2 Withdrawn
NCT04776980 2022-09-16
Multimodality MRI and Liquid Biopsy in GBM
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Withdrawn
NCT04200066 2022-08-22
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
Phase 1 Withdrawn
NCT01331616 2021-12-09
Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
West Penn Allegheny Health System
Phase EARLY_PHASE1 Withdrawn
NCT02283944 2021-09-20
TMS Electrochemotherapy for Glioblastoma Multiforme
University of Aarhus
Phase 2 Withdrawn
NCT04854044 2021-05-12
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03980249 2021-04-12
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
West Virginia University
Phase EARLY_PHASE1 Withdrawn
NCT04270461 2020-10-22
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Jiujiang University Affiliated Hospital
Phase 1 Withdrawn
NCT03506139 2020-09-09
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
University of Iowa
Phase 2 Withdrawn
NCT03014804 2020-07-24
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03973879 2020-02-11
Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
Duke University
Phase 1/2 Withdrawn
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00984438 2019-11-25
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
Phase 1/2 Withdrawn
NCT00977795 2019-09-10
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Endeavor Health
Phase 1/2 Withdrawn
NCT03480867 2019-08-14
PARADIGMA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 1 Withdrawn
NCT00814593 2019-05-10
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Lisata Therapeutics, Inc.
Phase 2 Withdrawn
NCT03185780 2018-11-28
Complementary/Integrative Medicine for Brain Cancer Patients
The Chaim Sheba Medical Center
Phase NA Withdrawn
NCT02540135 2018-07-20
Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma
University of Colorado, Denver
Phase NA Withdrawn
NCT03275558 2018-07-19
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Center Trials & Treatment
Phase 1 Withdrawn
NCT01788280 2018-02-07
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
University of Utah
Phase 2 Withdrawn
NCT02590497 2018-01-31
Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT01740570 2018-01-19
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02977689 2017-12-20
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT01413438 2017-07-02
Bevacizumab With or Without Surgery for Adult Glioblastomas
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02194452 2017-04-28
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
University of Iowa
Phase NA Withdrawn
NCT02876003 2017-02-24
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
GenSpera, Inc.
Phase 2 Withdrawn